Pharmaron Beijing Co., Ltd. (300759.SZ) has released its annual report for 2025. The company recorded operating revenue of 14.095 billion yuan, representing a year-on-year increase of 14.82%. However, net profit attributable to shareholders of the listed company was 1.664 billion yuan, a decrease of 7.22% compared to the previous year. After adjusting for non-recurring gains and losses, the net profit attributable to shareholders was 1.538 billion yuan, marking a significant growth of 38.85% year-on-year. Basic earnings per share stood at 0.9443 yuan.

Additionally, the company proposed a dividend distribution of 2 yuan per 10 shares (before tax) to all shareholders.

According to the announcement, Pharmaron continues to deepen its customer-centric service philosophy. By leveraging its integrated, end-to-end service platform and adhering to the highest international quality and regulatory standards, the company effectively utilizes the synergistic advantages of its operations in China, the UK, and the US to meet the diverse needs of global clients across various R&D stages.

In terms of strategic client development, the company has achieved significant results by deeply understanding and addressing customer requirements, with business from large pharmaceutical enterprises performing particularly well. Pharmaron is also expanding its client base, empowering customer drug discovery with cutting-edge technologies. While maintaining its industry leadership in small molecules, the company has seen rapid development in projects involving new molecular types.

For the Chinese market, Pharmaron is actively implementing market strategies better tailored to local conditions. As the internationalization of China's innovative drug sector accelerates, the company's business with Chinese clients has experienced rapid growth. In 2025, the value of newly signed orders increased by more than 14% compared to the previous year.